Sign In
Buy DRUG
$74.42
-2.36 (-3.07%)
At Close: Jun 03, 2026
Bright Minds Biosciences has standout year with epilepsy drug in Phase II trials
01:24pm, Monday, 15'th Dec 2025
For three decades, central nervous system (CNS) drug development was a tough space for investors, scarred by failed bets on Alzheimer's disease, plateauing first-generation antidepressants,
Recent Price Trend in Bright Minds Biosciences Inc. (DRUG) is Your Friend, Here's Why
09:55am, Wednesday, 26'th Nov 2025
Bright Minds Biosciences Inc. (DRUG) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Bright Minds Biosciences to Present at Piper Sandler 37th Annual Healthcare Conference and 2025 AES Annual Meeting
04:30pm, Tuesday, 25'th Nov 2025
NEW YORK, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly select
Wall Street Analysts Think Bright Minds Biosciences Inc. (DRUG) Could Surge 36.27%: Read This Before Placing a Bet
10:56am, Tuesday, 25'th Nov 2025
The average of price targets set by Wall Street analysts indicates a potential upside of 36.3% in Bright Minds Biosciences Inc. (DRUG). While the effectiveness of this highly sought-after metric is qu
Why Bright Minds Biosciences Stock Topped the Market on Monday
05:29pm, Monday, 17'th Nov 2025
Days after starting a new investigational program, it announced four appointments to its scientific advisory board. All of these professionals are experts in the affliction being targeted.
Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Experts in Prader-Willi Syndrome (PWS)
06:50am, Monday, 17'th Nov 2025
-- Tania Markovic MBBS PhD FRACP; Jennifer L. Miller, MD; Elizabeth Roof, H.S.P., M.A.; and Theresa V. Strong, PhD; distinguished global experts in PWS, will support the Company's PWS program, which w
Bright Minds Biosciences Initiates New Prader-Willi Syndrome (PWS) Program; KOL Event Scheduled for November 6TH
06:30am, Thursday, 06'th Nov 2025
-- Company will host a webcast at 10am ET on November 6, 2025, to discuss its Phase 2a study to assess efficacy, safety and tolerability of BMB-101 (NOVA Study) for the treatment of patients with Prad
Bright Minds Biosciences Inc. (DRUG) is on the Move, Here's Why the Trend Could be Sustainable
09:50am, Wednesday, 15'th Oct 2025
Bright Minds Biosciences Inc. (DRUG) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks tha
Wall Street Analysts Believe Bright Minds Biosciences Inc. (DRUG) Could Rally 81.29%: Here's is How to Trade
10:56am, Thursday, 18'th Sep 2025
The consensus price target hints at an 81.3% upside potential for Bright Minds Biosciences Inc. (DRUG). While empirical research shows that this sought-after metric is hardly effective, an upward tren
Does Bright Minds Biosciences Inc. (DRUG) Have the Potential to Rally 114.07% as Wall Street Analysts Expect?
10:55am, Tuesday, 02'nd Sep 2025
The consensus price target hints at an 114.1% upside potential for Bright Minds Biosciences Inc. (DRUG). While empirical research shows that this sought-after metric is hardly effective, an upward tre
STEALTH BIOTHERAPEUTICS RESUBMITS NEW DRUG APPLICATION FOR ELAMIPRETIDE FOR THE TREATMENT OF BARTH SYNDROME
08:00am, Monday, 18'th Aug 2025
NEEDHAM, Mass. , Aug. 18, 2025 /PRNewswire/ -- Stealth BioTherapeutics, a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for disea
Bright Minds Biosciences Announces Featured Speakers for its Absence Epilepsy Virtual R&D Day on May 20, 2025
08:00am, Tuesday, 20'th May 2025
- Key Opinion Leaders (KOLs) on Absence seizures include Dennis Dlugos, MD, Wendyl D'Souza, MBChB, MPH, FRACP, PhD, and Alexander Rotenberg, MD, PhD -
Epilepsy-Focused Bright Minds Biosciences A High-Risk, High-Reward Play, Analyst Initiates With Over 150% Stock Upside
04:45pm, Wednesday, 07'th May 2025
Chardan Research initiated coverage on Wednesday of Bright Minds Biosciences Inc. DRUG, an epilepsy drug developer.
VANCOUVER, British Columbia, April 28, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”), a company focused on developing high
Bright Minds Biosciences: A Buy With A Major Catalyst In Q2 2025
12:09pm, Wednesday, 16'th Apr 2025
We are initiating coverage of Bright Minds Biosciences with a Buy rating, as we believe the stock is undervalued. We see a key catalyst in the Phase 2 data readout for BMB-101, which is expected in Q2
